Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > Lorlatinib CAS 1454846-35-5

Lorlatinib CAS 1454846-35-5

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 1454846-35-5

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15 days

Payment Terms: T/T, L/C, D/A, Western Union

Supply Ability: TON

Get Best Price
Highlight:
CAS NO::
1454846-35-5
Appearance::
White To Off-white Solid
Molecular Formula::
C21H19FN6O2
Molecular Weight::
406.41300
EINECS NO::
813-704-5
MDL NO::
NA
CAS NO::
1454846-35-5
Appearance::
White To Off-white Solid
Molecular Formula::
C21H19FN6O2
Molecular Weight::
406.41300
EINECS NO::
813-704-5
MDL NO::
NA
Lorlatinib CAS 1454846-35-5

Product Description:

Product Name: Lorlatinib CAS NO: 1454846-35-5

 

 

 

Synonyms:

PF 06463922;

PF-06463922 Lorlatinib;

 

 

 

Chemical & Physical Properties:

Appearance: White to off-white solid

Assay :≥98.0%

Density 1.42±0.1 g/cm3 (Predicted)

Boiling point: 675.0±55.0℃(Predicted)

Storage: -20℃

Stability: ≥ 2 years

Pka: 6.05±0.40 (Predicted)

 

 

 

Safety Information:

Signal Word: Warning

Hazard Statements: H302

Caution Statements: P280-P305+P351+P338

Store Condiiton: Powder -20℃ 3 years 4℃2 years ;In solvent -80℃ 6 months -20℃1 month

 

 

 

Lorlatinib (PF-06463922) is a new drug under development for the sub-group of advanced non-small cell lung cancerwho are ALK or ROS1 positive and have already undergone gene treatment with drugs thatspecifically targetthis type of cancer.Lorlatinib is currently being evaluated in phase II clinical trials as an oral dose at 100 mg daily. If marketed it will becomean additional targeted treatment for this sub-group of ALKor ROS1 positive patients.

Lorlatinib acts by inhibiting the ALK and ROS1 receptor tyrosine kinases, with potent activity against a broad spectrum of ALK resistant mutations. By inhibiting ALK phosphorylation and ROS1 activity, lorlatinib inhibits the downstream signalling, thereby inducing the apoptosis process, which results in the inhibition of tumour cells proliferation.

Due to tumor complexity and development of resistance to treatment, disease progression is a challenge in patients with ALK-positive metastatic non-small cell lung cancer (NSCLC). A common site for progression in metastatic NSCLC is the brain.

Lorlatinib was specifically designed to inhibit tumor mutations that drive resistance to other ALK inhibitors and to penetrate the blood brain barrier.

 

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.